Compare QSI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QSI | SGHT |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | 145 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.8M | 187.4M |
| IPO Year | N/A | 2021 |
| Metric | QSI | SGHT |
|---|---|---|
| Price | $0.90 | $4.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.00 | ★ $9.08 |
| AVG Volume (30 Days) | ★ 5.0M | 367.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | $618.07 | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.69 | $2.74 |
| 52 Week High | $3.10 | $9.24 |
| Indicator | QSI | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 58.39 |
| Support Level | $0.69 | $3.30 |
| Resistance Level | $1.10 | $5.32 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 42.69 | 52.55 |
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.